Last mentioned: 2d ago
Anticipated Filing
Expected regulatory submission for WVE-N531 in Duchenne muscular dystrophy.
FY 2025 Earnings
Wave and Collegium release full-year financial results and 2026 guidance.
RNA Editing Milestone
WVE-006 demonstrates successful RNA editing in AATD patients.
DMD Breakthrough
Wave reports industry-leading dystrophin expression for WVE-N531.
A new feasibility study indicates that maternal immunization programs can be successfully integrated into existing antenatal care frameworks, provided systemic gaps are addressed. Key challenges include cold chain logistics, healthcare worker training, and the need for digital tracking systems to monitor neonatal outcomes.
The CDC has issued a series of travel notices for popular international tourist destinations following a spike in polio detections. The move signals a shift in global health security, requiring travelers to verify immunization status and potentially seek adult boosters before departure.
Wave Life Sciences and Collegium Pharmaceutical released their Q4 and full-year 2025 results, highlighting a pivotal year for RNA editing and specialty pain management. Wave's transition toward a commercial-stage biotech is accelerated by its GSK partnership and landmark clinical data in Alpha-1 antitrypsin deficiency.